RecruitingNot Applicable

Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety

United States180 participantsStarted 2022-08-22

Plain-language summary

Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).
✓. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their "primary" mental disorder:
✓. No current use of psychotropic medications or stable on current medications for at least 6 weeks
✓. Age 18+.
✓. Able to arrange transportation to our laboratory for study appointments.
✓. Fluent in English.

Exclusion criteria

✕. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:
✕. Not currently receiving other psychological treatment for anxiety.
✕. No history of a suicide attempt within the past 6 months.
✕. No history of psychosis within the past 6 months.
✕. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.
✕. Does not endorse COVID-19 symptoms during the screening phase.

What they're measuring

Overall Anxiety Severity and Impairment Scale

Timeframe: Pre-Treatment (Week 0), Post-treatment (Week 5), 2-Month Follow-Up (Week 13)

Computerized Hamilton Anxiety Scale

Timeframe: Pre-Treatment (Week 0), Post-treatment (Week 5), 2-Month Follow-Up (Week 13)

Trial details

NCT IDNCT05427708

SponsorUniversity of Texas at Austin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-05

Contact for this trial

Michael J Telch, PhD

512-814-5480 telch@austin.utexas.edu

View on ClinicalTrials.gov More Anxiety Disorders trials